Provided by Tiger Trade Technology Pte. Ltd.

Quoin Pharmaceuticals

5.57
+0.580011.62%
Post-market: 5.40-0.1670-3.00%19:30 EDT
Volume:72.11K
Turnover:391.82K
Market Cap:11.19M
PE:-0.53
High:5.88
Open:5.29
Low:5.02
Close:4.99
52wk High:41.80
52wk Low:3.25
Shares:2.01M
Float Shares:1.63M
Volume Ratio:2.98
T/O Rate:4.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.4278
EPS(LYR):-14.7963
ROE:-575.73%
ROA:-114.60%
PB:2.84
PE(LYR):-0.38

Loading ...

Company Profile

Company Name:
Quoin Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
5
Office Location:
42127 Pleasant Forest Court,Ashburn,Virginia,United States
Zip Code:
20148-7349
Fax:
- -
Introduction:
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.

Directors

Name
Position
Michael Myers
Chairman of the Board,Chief Executive Officer and Director
Denise Carter
Chief Operating Officer and Director
Dennis H. Langer
Independent Director
James Culverwell
Independent Director
Joseph Cooper
Independent Director
Michael Sember
Independent Director
Natalie Leong
Independent Director

Shareholders

Name
Position
Michael Myers
Chairman of the Board,Chief Executive Officer and Director
Denise Carter
Chief Operating Officer and Director
Sally Lawlor
Chief Financial Officer